The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders
Open accessAbstract
Although the global prevalence of neurological disorders such as Parkinson’s disease, Alzheimer’s disease, glioblastoma, epilepsy, and multiple sclerosis is steadily increasing, effective delivery of drug molecules in therapeutic quantities to the central nervous system (CNS) is still lacking. The blood brain barrier (BBB) is the major obstacle for the entry of drugs into the brain, as it comprises a tight layer of endothelial cells surrounded by astrocyte foot processes that limit drugs’ entry. In recent times, intranasal drug delivery has emerged as a reliable method to bypass the BBB and treat neurological diseases. The intranasal route for drug delivery to the brain with both solution and particulate formulations has been demonstrated repeatedly in preclinical models, including in human trials. The key features determining the efficacy of drug delivery via the intranasal route include delivery to the olfactory area of the nares, a longer retention time at the nasal mucosal surface, enhanced penetration of the drugs through the nasal epithelia, and reduced drug metabolism in the nasal cavity. This review describes important neurological disorders, challenges in drug delivery to the disordered CNS, and new nasal delivery techniques designed to overcome these challenges and facilitate more efficient and targeted drug delivery. The potential for treatment possibilities with intranasal transfer of drugs will increase with the development of more effective formulations and delivery devices.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxic potential of materials at the nanolevel
Nel, A., Xia, T., Mädler, L., & Li, N. (2006) · Science · doi:10.1126/science.1114397 · Cited by 9,324
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
ILAE official report: a practical clinical definition of epilepsy
Fisher, R. S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J. H., Elger, C. E., Engel, J., Forsgren, L., French, J. A., Glynn, M., et al. (2014) · Epilepsia · doi:10.1111/epi.12550 · Cited by 6,108
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Ha, D., Yang, N., & Nadithe, V. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.02.001 · Cited by 1,346
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Transport of drugs from the nasal cavity to the central nervous system
Illum, L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00087-7 · Cited by 907
Enhanced Permeability and Retention (EPR) Effect for Anticancer Nanomedicine Drug Targeting
Greish, K. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-609-2_3 · Cited by 841
Mechanism of intranasal drug delivery directly to the brain
Crowe, T. P., Greenlee, M. H. W., Kanthasamy, A. G., & Hsu, W. H. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.12.025 · Cited by 721
Transport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715
Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier
Lockman, P. R., Mumper, R. J., Khan, M. A., & Allen, D. D. (2002) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120001481 · Cited by 592
Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review
Djupesland, P. G. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-012-0108-9 · Cited by 563
Intranasal nanoemulsion based brain targeting drug delivery system of risperidone
Kumar, M., Misra, A., Babbar, A. K., Mishra, A. K., Mishra, P., & Pathak, K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.03.029 · Cited by 435
Functionalized gold nanoparticles: Synthesis, structure and colloid stability
Zhou, J., Ralston, J., Sedev, R., & Beattie, D. A. (2009) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2008.12.002 · Cited by 417
The biopharmaceutical aspects of nasal mucoadhesive drug delivery
Ugwoke, M. I., Verbeke, N., & Kinget, R. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011775145 · Cited by 355
Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism
Parker, K. J., Oztan, O., Libove, R. A., Sumiyoshi, R. D., Jackson, L. P., Karhson, D. S., Summers, J. E., Hinman, K. E., Motonaga, K. S., Phillips, J. M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705521114 · Cited by 349
Mohamed, F., & van der Walle, C. F. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21082 · Cited by 299
Aisen, P. S., Gauthier, S., Ferris, S. H., Saumier, D., Haine, D., Garceau, D., Duong, A., Suhy, J., Oh, J., Lau, W. C., et al. (2011) · Archives of Medical Science · doi:10.5114/aoms.2011.20612 · Cited by 295
Georgieva, J., Hoekstra, D., & Zuhorn, I. (2014) · Pharmaceutics · doi:10.3390/pharmaceutics6040557 · Cited by 211
Yang, T., Fogarty, B., LaForge, B., Aziz, S., Pham, T., Lai, L., & Bai, S. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0015-y · Cited by 204
Evidence of nose-to-brain delivery of nanoemulsions: Cargoes but not vehicles
Ahmad, E., Feng, Y., Qi, J., Fan, W., Ma, Y., He, H., Xia, F., Dong, X., Zhao, W., Lu, Y., et al. (2017) · Nanoscale · doi:10.1039/c6nr07581a · Cited by 194
Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting
Kumar, M., Misra, A., Mishra, A. K., Mishra, P., & Pathak, K. (2008) · Journal of Drug Targeting · doi:10.1080/10611860802476504 · Cited by 179
Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (bbb).
Kreuter, J. (2013) · Journal of Microencapsulation · doi:10.3109/02652048.2012.692491 · Cited by 172
Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion
Abdou, E. M., Kandil, S. M., & Miniawy, H. M. F. E. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.030 · Cited by 124
DCE-MRI blood–brain barrier assessment in acute ischemic stroke
Villringer, K., Sanz Cuesta, B. E., Ostwaldt, A.-C., Grittner, U., Brunecker, P., Khalil, A. A., Schindler, K., Eisenblätter, O., Audebert, H., & Fiebach, J. B. (2017) · Neurology · doi:10.1212/wnl.0000000000003566 · Cited by 119
Candela, P., Gosselet, F., Miller, F., Buee-Scherrer, V., Torpier, G., Cecchelli, R., & Fenart, L. (2008) · Endothelium · doi:10.1080/10623320802487759 · Cited by 117
Shah, B., Khunt, D., Misra, M., & Padh, H. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.04.076 · Cited by 112 · cited 3×
“Compared to an intranasal solution, quetiapine chitosan nanoparticles enhanced the drug delivery to the brain by 34% [179].”
BackgroundInfluentialDelivery of oxytocin to the brain for the treatment of autism spectrum disorder by nasal application
Tanaka, A., Furubayashi, T., Arai, M., Inoue, D., Kimura, S., Kiriyama, A., Kusamori, K., Katsumi, H., Yutani, R., Sakane, T., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00991 · Cited by 104
Ho, L., Yemul, S., Knable, L., Katsel, P., Zhao, R., Haroutunian, V., & Pasinetti, G. M. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/321280 · Cited by 21
Cited by
Costa, C. P., Moreira, J. N., Sousa Lobo, J. M., & Silva, A. C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.012 · Cited by 303
On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles
Formica, M. L., Real, D. A., Picchio, M. L., Catlin, E., Donnelly, R. F., & Paredes, A. J. (2022) · Applied Materials Today · doi:10.1016/j.apmt.2022.101631 · Cited by 282
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
Ouyang, Q., Liu, K., Zhu, Q., Deng, H., Le, Y., Ouyang, W., Yan, X., Zhou, W., & Tong, J. (2022) · Small · doi:10.1002/smll.202107534 · Cited by 94
Liu, N., Yang, C., Liang, X., Cao, K., Xie, J., Luo, Q., & Luo, H. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01642-z · Cited by 45
Metadata
- Authors
- Islam, S. U., Shehzad, A., Ahmed, M. B., & Lee, Y. S.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-04-21
- Volume
- 25
- Issue
- 8
- Pages
- 1929
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3018226629
- Cited by
- 184
- References
- 36
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.